TY - JOUR
T1 - Septic shock in the immunocompromised cancer patient
T2 - a narrative review
AU - Nates, Joseph L.
AU - Pène, Frédéric
AU - Darmon, Michael
AU - Mokart, Djamel
AU - Castro, Pedro
AU - David, Sascha
AU - Povoa, Pedro
AU - Russell, Lene
AU - Nielsen, Nathan D.
AU - Gorecki, Gabriel Petre
AU - Gradel, Kim O.
AU - Azoulay, Elie
AU - Bauer, Philippe R.
N1 - Funding Information:
This work was supported by a discretionary fund from the Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Immunosuppressed patients, particularly those with cancer, represent a momentous and increasing portion of the population, especially as cancer incidence rises with population growth and aging. These patients are at a heightened risk of developing severe infections, including sepsis and septic shock, due to multiple immunologic defects such as neutropenia, lymphopenia, and T and B-cell impairment. The diverse and complex nature of these immunologic profiles, compounded by the concomitant use of immunosuppressive therapies (e.g., corticosteroids, cytotoxic drugs, and immunotherapy), superimposed by the breakage of natural protective barriers (e.g., mucosal damage, chronic indwelling catheters, and alterations of anatomical structures), increases the risk of various infections. These and other conditions that mimic sepsis pose substantial diagnostic and therapeutic challenges. Factors that elevate the risk of progression to septic shock in these patients include advanced age, pre-existing comorbidities, frailty, type of cancer, the severity of immunosuppression, hypoalbuminemia, hypophosphatemia, Gram-negative bacteremia, and type and timing of responses to initial treatment. The management of vulnerable cancer patients with sepsis or septic shock varies due to biased clinical practices that may result in delayed access to intensive care and worse outcomes. While septic shock is typically associated with poor outcomes in patients with malignancies, survival has significantly improved over time. Therefore, understanding and addressing the unique needs of cancer patients through a new paradigm, which includes the integration of innovative technologies into our healthcare system (e.g., wireless technologies, medical informatics, precision medicine), targeted management strategies, and robust clinical practices, including early identification and diagnosis, coupled with prompt admission to high-level care facilities that promote a multidisciplinary approach, is crucial for improving their prognosis and overall survival rates. Graphical abstract: (Figure presented.)
AB - Immunosuppressed patients, particularly those with cancer, represent a momentous and increasing portion of the population, especially as cancer incidence rises with population growth and aging. These patients are at a heightened risk of developing severe infections, including sepsis and septic shock, due to multiple immunologic defects such as neutropenia, lymphopenia, and T and B-cell impairment. The diverse and complex nature of these immunologic profiles, compounded by the concomitant use of immunosuppressive therapies (e.g., corticosteroids, cytotoxic drugs, and immunotherapy), superimposed by the breakage of natural protective barriers (e.g., mucosal damage, chronic indwelling catheters, and alterations of anatomical structures), increases the risk of various infections. These and other conditions that mimic sepsis pose substantial diagnostic and therapeutic challenges. Factors that elevate the risk of progression to septic shock in these patients include advanced age, pre-existing comorbidities, frailty, type of cancer, the severity of immunosuppression, hypoalbuminemia, hypophosphatemia, Gram-negative bacteremia, and type and timing of responses to initial treatment. The management of vulnerable cancer patients with sepsis or septic shock varies due to biased clinical practices that may result in delayed access to intensive care and worse outcomes. While septic shock is typically associated with poor outcomes in patients with malignancies, survival has significantly improved over time. Therefore, understanding and addressing the unique needs of cancer patients through a new paradigm, which includes the integration of innovative technologies into our healthcare system (e.g., wireless technologies, medical informatics, precision medicine), targeted management strategies, and robust clinical practices, including early identification and diagnosis, coupled with prompt admission to high-level care facilities that promote a multidisciplinary approach, is crucial for improving their prognosis and overall survival rates. Graphical abstract: (Figure presented.)
KW - Critical care
KW - Critical care outcomes
KW - Hematologic neoplasms
KW - Hematopoietic stem cell transplantation
KW - Immunocompromised host
KW - Neoplasms
KW - Organ transplantation
KW - Septic shock
UR - http://www.scopus.com/inward/record.url?scp=85202930184&partnerID=8YFLogxK
U2 - 10.1186/s13054-024-05073-0
DO - 10.1186/s13054-024-05073-0
M3 - Review article
C2 - 39215292
AN - SCOPUS:85202930184
SN - 1364-8535
VL - 28
JO - Critical Care
JF - Critical Care
IS - 1
M1 - 285
ER -